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Despite the apparent beneficial effects of probiotics/synbiotics on glucose hemostasis, lipid 
profile, and inflammatory responses, it is not clear whether these beneficial effects also impact 
renal and hepatic function in diabetes. Therefore, we sought to assess the effect of 
probiotics/synbiotics supplementation on renal and liver biomarkers in adults with type 2 
diabetes (T2DM) using a systematic review and meta-analysis of randomized controlled trials 
(RCTs). PubMed, Scopus, Web of Science, and Cochrane Library were systematically searched, 
up to February 2021. The pooled weighted mean difference (WMD) was estimated using a 
random-effect model. The methodological quality of studies, as well as certainty of evidence, 
was assessed using standard scales. Fifteen related trials were identified. Meta-analysis of six 
trials, involving 426 participants, indicated that probiotics/synbiotics supplementation reduced 
serum levels of creatinine (WMD= -0.10 mg/dl, 95% CI: -0.20, -0.00; P= 0.01; I2= 87.7%; P-
heterogeneity<0.001), without any significant effect on blood urea nitrogen (BUN), glomerular 
filtration rate, or microalbuminuria. No significant improvement was found on liver biomarkers 
following probiotics/synbiotics supplementation. The subgroup analysis showed a significant 
improvement in BUN when follow-up duration lasted for 12 weeks or more (WMD= -1.215 
mg/dl, 95% CI: -1.933, -0.496  ; P= 0.001), and in creatinine levels in patients with renal 
dysfunction (WMD= -0.209 mg/dl, 95% CI: -0.322, -0.096; P<0.001). Our results are 
insufficient to advocate the use of probiotics/synbiotics for improving renal or liver function in 
patients with T2DM. Indeed, due to the low certainty of evidence, these findings need to be 
affirmed in further high-quality RCTs. 
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With the increasing prevalence of obesity, sedentary lifestyles, and urbanization, type 2 diabetes 
mellitus (T2DM) has become a global health issue, affecting 463 million people in 2019, and is 
predicted to reach 700 million cases in 2045 (1). T2DM can lead to a series of additional 
complications, particularly micro- and macro-vascular damage, and negatively affecting multiple 
vital organs, including the kidneys, liver, eyes, and cardiovascular system (2).  
Studies have reported that 20-40% of patients with diabetes suffer from renal dysfunction, 
characterized by urine albumin excretion or reduced glomerular filtration rate (GFR), and 40% of 
them may progress to end stage renal disease (ESRD) (3-6). The exact cause of diabetic renal 
impairment is complex, and is proposed to be contributed to hyperglycemia, dyslipidemia, 
atherosclerotic vascular, obesity, hyperuricemia, and increased systemic and intra-glomerular 
pressure (7, 8).  
Accumulating evidence also indicates that the liver, as an insulin-sensitive tissue and the main 
regulator of metabolism, is prone to damage by hyperglycemia, leading to further impaired 
metabolism and inflammatory reactions (9, 10). Steatosis, elevated liver enzymes, cirrhosis, and 
carcinoma are among several important liver abnormalities in patients with T2DM (11, 12).  
The most well-known strategy to prevent the progression of diabetes-related complications is 
maintaining glycemic control (13). In addition to weight control, lifestyle modifications, and 
medical solutions, there is evidence supporting the effect of gut microbiome in regulating 
metabolism and energy hemostasis (14, 15). Recently, studies reported alternations of gut 
microbiota in patients with diabetes (16-18), and probiotics/synbiotics supplementation was able to 
exert beneficial effects on lipid profile, glycemic control, blood pressure, and inflammation in 
these patients (19-25).   
The exact mechanism of beneficial effects manifest following probiotic supplementation is not 
well known. However, its anti-inflammatory properties are very likely contributory. A recent 
meta-analysis study showed that probiotic therapy significantly decreased C-reactive protein 
concentration, and increased serum levels of glutathione, malondialdehyde, and total antioxidant 
capacity in patients with chronic kidney diseases (22). Moreover, probiotics may improve insulin 
resistance by increasing liver natural killer T cells, and downregulating tumor necrosis factor α 
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(TNF-α) and Nuclear factor-κB (NF-κB) activity (26). Probiotics have also shown angiotensin-
converting enzyme (ACE) inhibitor properties, and consequential antihypertensive effects (20, 27).  
Although there is evidence regarding the beneficial effects of probiotics/synbiotics on the 
improvement of metabolic control in patients with diabetes (24, 25, 28-30), so far, no study has 
systematically examined the effects of probiotics/synbiotics on renal and liver function in these 
patients. Therefore, we sought to investigate whether probiotic supplementation could improve 
renal and liver biomarkers, by conducting a systematic and meta-analysis of randomized clinical 
trials (RCTs). 
METHODS 
We performed the present meta-analysis in accordance with the Cochrane Handbook for 
Systematic Reviews of Interventions and (31) adhered the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (32). This review was registered at 
in the center of Open Science Framework (OSF) as  https://doi.org/10.17605/OSF.IO/UKXBD. 
Search strategy  
We searched for references indexed in PubMed, Scopus, Web of Science, and Cochrane Library, 
from database inception to 10 February 2021. The terms used in search strategy are provided in 
Supplementary Table 1. We did not impose any keywords in term of interested outcomes and 
did not apply any restriction for language or publication year. The reference lists of the meta-
analyses that examined the effect of probiotic or synbiotic supplementation/fortified foods in 
T2DM were also searched manually. A specific question was also defined according to the 
PICOS principle (Participants, Interventions, Control, Outcomes, and Study design) (Table 1).  
Selection criteria 
The titles/abstracts and full text of retrieved references were screened according to the inclusion 
and exclusion criteria independently by two authors (SS and FM), and any discrepancies were 
resolved by discussion with a third author (SA). The inclusion criteria of this article were as 
follows: the RCTs (parallel or crossover) that compared the effects of probiotic/synbiotic 
supplements or fortified foods (any strains and dosages) with placebo in pre-diabetic or T2DM 
patients. All included studies needed to report mean and standard deviation of baseline, post, or 
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change from baseline for at least one of the following liver enzymes or kidney function 
indicators, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma 
glutamyl transferase (GGT), alkaline phosphatase (ALP), bilirubin, creatinine, blood urea 
nitrogen (BUN), uric acid, microalbuminuria, proteinuria, or GFR, or any other renal and liver 
biomarkers. The exclusion criteria were as follows: (1) trials with less than one-week period, (2) 
trials without a placebo controlled group, (3) duplicated publications from the same population, 
(4) trials with insufficient information for calculating the mean or standard deviation (SD) 
change in the outcome measure(s), (5) trials including pregnant or lactating women, and (6) trials 
that used probiotic or synbiotic in combination with other treatments and/or the comparator 
group did not received the same treatment. 
Data extraction 
The relevant data was extracted by one author and then cross-checked by another (SS, FM), and 
any discrepancies resolved by discussion with a third author (SA). The following data was 
extracted: the first author’s name, year of publication, study characteristic (study design, follow-
up duration, study location, sample size in the intervention and control groups, the species and 
dosage of probiotic or synbiotic supplementation, and interested outcomes), and participant 
characteristic (age, sex, health status). The means, along with the respective SDs values, of 
before and after the intervention or change for AST (U/L), ALT (U/L), GGT (U/L), ALP (U/L), 
bilirubin (mg/dl), creatinine (mg/dl), BUN (mg/dl), microalbuminuria (albumin/creatinine ratio), 
GFR (mL/min/1.73m2), and any other liver or renal related biomarkers also were extracted. 
Study quality and Quality of evidence 
The quality of the selected articles were evaluated using the Cochrane Collaboration’s tool for 
assessing risk of bias (33). The quality of evidence assessment was performed with the use of the 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, 
which includes five domains: risk of bias, inconsistency of results, imprecision of results, 
indirectness of evidence, and publication bias. The quality of evidence of a RCTs was initially 
considered as high and was downgraded by the following limitations: methodological errors (34), 
inconsistency (35), imprecision of estimates (36), indirectness (37), or evidence of publication bias 
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(38). All quality evaluation and evidence were performed independently by two reviewers (SS and 
FM), and disagreements were resolved through discussion with a third author (SA). 
Statistical analyses  
For each outcome, where at least ≥3 RCTs reported sufficient data, the net change in mean and 
it’s 95% CI between the intervention and control groups as the effect size calculate in the meta-
analysis. In term of trials that did not provide change values, the mean difference was calculated 
by minus mean changes the intervention mean minus the control group mean, and standard 
deviation of the mean change estimated formula suggested by the Cochrane Handbook of  
Systematic Review (39) where correlation coefficient was imputed [r=0.68 ALP (40), r= 0.42 AST 
(41-43), r= 0.48 ALT (41), r= 0.73 bilirubin (41, 42), r=0.82 creatinine (44-48), r=0.71 BUN (45-47, 49), 
r=0.77 microalbuminuria (40, 46), r=0.82 GFR (44, 48)] from included studies reporting both 
baseline, final values and changes from baseline for each interested outcome. The random-effects 
model described by Dersimonian and Laird was used to calculate the overall pooled effect (50).  
Regarding trials that multiple intervention (probiotic or synbiotic) compared with the single 
control group, the calculated effect size related to probiotic supplementation were included in 
main analysis to avoid counting the control group twice in the analysis. 
Inconsistencies across trials were assessed with the use of the Cochrane’s chi-squared test and 
the I2 statistic, where significant heterogeneity was evident as I2 ≥ 50% (51, 52). The subgroup 
analyses were conducted to detect source of heterogeneity if there are adequate trials for each 
outcome. Sensitivity analysis were conducted to evaluate the impacts of each trial on the meta-
analysis results. The presence of publication bias was evaluated by the “Begg’s funnel plot” and 
Egger’s test whenever if possible (at least 10 trials included) (53, 54). Statistical analyses were 
conducted using STATA version 14 (STATA Corp., College Station, Texas). Two-tailed P 





Study selection and characteristics 
The study selection process detailed in Figure 1. Our initial systematic search identified 4905 
potentially relevant studies, after removing duplicates (n= 1348). Following title/abstract review, 
98 articles were retained for full-text screening, and then, 83 further articles were excluded due 
to the wrong population (n=4), wrong intervention (n=16), wrong outcome (n=51), wrong 
comparison (n=2), insufficient data (n=1), repeated reports (n=6), and without full-text (n=3).  
The excluded studies as well as the reasons are shown in Supplementary Table 2. Finally, 15 
trials were eligible for inclusion in the systematic review, and reported following outcomes: ALP 
(n=4), ALT (n=6), AST (n=6), bilirubin (n=3), BUN (n=5), creatinine (n=6), GFR (n=3), 
microalbuminuria (n=3), uric acid (n=2), cystatin-C (n=1), albumin (n=1), γ-GT (n=1), and 
neutrophil gelatinase-associated lipocalin (NGAL) (n=1). 
The studies characteristics are described in Table 2. Except for two studies (41, 42), all the 
included studies were parallel in design. Most of the included studies were carried out in Iran (40-
48, 55-57), and the rest of the studies were performed in Ukraine (58), Sweden (59), and Malaysia (60). 
Participants were composed of both male and female in all the included studies, and were with 
T2DM; although, patients with both type 1 and type 2 diabetes were eligible for inclusion in two 
studies (47, 48), and one study did not provide information about the type of diabetes (45). 
Participants in seven studies suffered from nephropathy (40, 44, 45, 47, 57, 59), dialysis (48), and non-
alcoholic fatty liver (58). The mean baseline BMI presented an obesity (>30 kg/m2) condition in 
six studies (42, 43, 45, 56, 58, 59), and participants in other studies were in overweight category. 
Participants in five studies were treated with exogenous insulin (47, 48, 57-59), and oral anti-
hyperglycemic drugs were given in rest of the studies.    
The duration of intervention ranged from six to 12 weeks. All the included studies administered 
synbiotics (46) or probiotics (47, 48, 55, 56, 58-60) in solid pharmaceutical formulations (powder or table 
form), and six studies used soy milk (40, 57), bread (43), honey (45), and an unknown food containing 
synbiotic (41, 42) as carrier. One study included two doses of probiotic, where the higher dose was 
considered for analysis (59). There was also one study that presented data on synbiotic, probiotic, 
and placebo supplementation, separately, where the probiotic in comparison with placebo was 
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included in the analysis (43). Common adverse effects were reported, such as gastric disturbance 
(59, 60), headache, hypoglycemia, and musculoskeletal symptoms (59). 
Risk of bias and quality of evidence 
The Cochrane Collaboration’s tool was used to assess the methodological quality of studies. 
Participants, personnel, and outcomes assessor were blind in all the included studies. Of the 15 
included randomized studies, two did not describe the randomization, and allocation 
concealment process (40, 59). Furthermore, one study was funded partly by a non-academic source, 
however, the authors declared no conflict of interest, and the company did not interfere with the 
decision to exploit research results; therefore, we did not downgrade for funding domain (60). No 
concern was also found about incomplete data or selective reporting. Altogether, most of the 
included studies were rated as good quality, and two studies were fair in methodological quality 
(40, 59) (Supplementary Table 3). The quality of evidence showed very low certainty for ALT, 
ALP, bilirubin, creatinine, GFR, and microalbuminuria, and low certainty for AST and BUN 
(Supplementary Table 4). 
Meta-analysis 
The effect of probiotics/synbiotics supplementation on liver biomarkers 
Pooling data from RCTs revealed probiotics/synbiotics supplementation had no significant effect 
on ALP (41, 43, 56, 60) (n= 4 studies, 310 participants; WMD= 7.26 U/L, 95% CI: -3.39, 17.91; P= 
0.18; I2= 63.3%; P-heterogeneity=0.04), ALT (41, 43, 56, 58-60) (n= 6 studies, 397 participants; 
WMD= -0.76 U/L, 95% CI: -4.12, 2.58; P= 0.65; I2= 57.7%; P-heterogeneity=0.03), AST (41, 43, 
56, 58-60) (n= 6 studies, 397 participants; WMD= -0.91 U/L, 95% CI: -3.05, 1.22; P= 0.4; I2= 28.1; 
P-heterogeneity=0.22), and bilirubin levels  (n= 3 studies, 256 participants; WMD= -0.04 mg/dl, 
95% CI: -0.16, 0.08; P= 0.52; I2= 86.2%; P-heterogeneity= 0.001) (Figure 2, Supplementary 
Table 5). Between-study heterogeneity was moderate to high, although the small number of 
studies precluded a comprehensive subgroup analysis, the duration of intervention, and liver 





The effect of probiotics/synbiotics supplementation on renal biomarkers 
Our analysis found probiotics/synbiotics supplementation reduced creatinine levels (44-48, 60) (n= 6 
studies, 426 participants; WMD= -0.10 mg/dl, 95% CI: -0.20, -0.00; P= 0.01; I2= 87.7%; P-
heterogeneity<0.001), without any significant effect on GFR (44, 48, 60) (n= 3 studies, 236 
participants; WMD= 4.55 mL/min/1.73m2, 95% CI: -0.94, 10.05; P= 0.1; I2= 90.7%; P-
heterogeneity<0.001), microalbuminuria (40, 46, 59) (n= 3 studies, 139 participants; WMD= -10.36 
Alb/Cr (mg/gr), 95% CI: -22.87, 2.16; P= 0.1; I2= 80.9%; P-heterogeneity= 0.005), or BUN (45-48, 
60) (n= 5 studies, 386 participants; WMD= -0.87 mg/dl, 95% CI: -1.91, 0.18; P= 0.1; I2= 36.1%; 
P-heterogeneity= 0.18) (Figure 3, Supplementary Table 5). Subgroup analysis was performed 
when the number of studies was sufficient for each outcome, and the results showed a significant 
reduction in BUN levels when intervention lasted for 12 weeks or more (n= 4 studies, 316 
participants; WMD= -1.215 mg/dl, 95% CI: -1.933, -0.496  ; P= 0.001; I2= 0.0%; P-
heterogeneity=0.41), and also showed a significant reduction in creatinine levels in patients with 
renal complications (n= 4 studies, 220 participants; WMD=-0.209 mg/dl, 95% CI: -0.322, -
0.096; P<0.001; I2= 46.7%; P-heterogeneity= 0.13). Subgroup analysis also identified duration of 
intervention and renal complication as the potential source of heterogeneity.  
Outcomes did not analyze 
Uric acid. Two studies evaluated the effect of probiotic supplement and synbiotic food 
consumption on serum uric acid, and reached to contradictory results. One study found synbiotic 
food supplementation significantly increased serum uric acid (42), while other study revealed no 
significant effect following probiotic supplementation (56). 
γ-GT. One study suggested significant 12 percent decrease in serumγ-GT following a multi-
strain probiotic supplementation in type 2 diabetes patients with non-alcoholic fatty liver disease 
(58). 
Cystatin-C, NGAL. One study showed significant reduction in cystatin-c and marginally 
significant reduction in NGAL levels in patients with type 2 diabetic nephropathy after 




Sensitivity analysis and publication bias 
The leave-one out sensitivity analysis did not identify any study with a significant influence on 
the pooled effects sizes. An additional sensitivity analysis was conducted excluding the studies 
that examined synbiotic supplementation, and the results showed significant decreases in 
creatinine and BUN levels, with a significant reduction in between-study heterogeneity 
(Supplementary Table 7). Publication bias was not examined due to the insufficient study for 
each outcome. 
DISCUSSION 
This meta-analysis pooled data from RCTs investigating the effect of probiotics/synbiotics 
supplementation on kidney and liver parameters in patients with diabetes. Our results revealed 
probiotics/synbiotics supplementation has no significant effect on ALT, AST, ALP, BUN, 
bilirubin, GFR, or microalbuminuria. However, it was shown that probiotics/synbiotics may 
elicit beneficial effects on creatinine levels. 
Emerging data indicating gut microbiota modulation by probiotic, prebiotic or synbiotic 
supplementation can induce favorable effects on lipid profile, glycemic control (61), and 
antioxidant capacity in patients with diabetes (21). It has been suggested that inflammation is the 
major mechanism related to diabetes complications (62, 63). Indeed, patients with diabetes tend to 
suffer from chronic inflammation, exacerbated by impaired intestinal function (64). The gut is 
known as a potential immune regulation gate (65), and several immune, endocrine, and metabolic 
pathways accrue between intestinal and other organs (66). Short chain fatty acids (SCFAs), the 
main product of gut fermentation, reduce intestinal permeability, bacteria translocation (67), and 
downregulate the expression of pro-inflammatory cytokines (68). However, findings from 
previous meta-analysis are inconsistent (69, 70). It seems that the anti-inflammatory effects of 
probiotics are increased when combined with the prebiotics. Moreover, as shown in a meta-
analysis, the use of synbiotics may have more beneficial effects in reducing inflammatory factors 
than probiotics (70), because of the additional substrate for fermentation, and consequential 
growth stimulation of gut microbiota (71). However, our results showed a significant reduction in 
creatinine and BUN levels when analysis restricted to probiotic supplementation. It may be due 
to the higher dose of probiotic in the studies administered probiotic, exclusively. Moreover, BUN 
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levels improved in studies administered probiotic/synbiotic for 12 weeks or more. This 
association disappeared when a sensitivity analysis was conducted for studies with ≥8 weeks 
follow up duration (data not shown). It seems, more than 12 weeks intervention may exert 
greater beneficial effects of probiotics. However, the number of included studies in our analysis 
was not enough to draw a definitive conclusion.  
In line with a previous systematic review (72), we found probiotic/synbiotic supplementation may 
improve creatinine levels in patients with renal dysfunction. Although, a meta-analysis by 
AbdelQadir etal., showed despite a significant improvement in antioxidant indices, there is no 
association between probiotic supplementation and creatinine, GFR, or BUN levels in patients 
with diabetic nephropathy (73). It may be contributed to misclassification of the study by Firouzi 
etal., (60) which the nephropathy was an exclusion criterion of this study, but it has been included 
in the analysis.  
It is suggested probiotic may improve renal function through increasing anaerobic bacteria such 
as Lactobacillus and Bifidobacterium leading to decrease PH and urea levels. Moreover, some 
probiotic species such as Bacteroides can reduce urea by their urease activity (74). However, our 
analysis found no significant association for other renal biomarkers. There is accumulating 
evidence suggesting some new biomarkers for kidney function, such as cystatin-C or NGAL, are 
more affected in early stages of kidney injuries than BUN, or GFR (71, 72). The Northern 
Manhattan study also indicated that cystatin-C based GFR may be a better predictor of all-cause 
mortality in the elderly, in comparison to serum creatinine (73). However, in our study, data 
were not enough to perform a meta-analysis on these predictor biomarkers. 
Concordant with our findings, several previous studies showed contradictory effects of probiotic 
supplementation on liver enzymes in patients with diabetes (43, 60), or fatty liver diseases (75-77). As 
a possible explanation, metformin, which was used by most of our included studied population, 
is known to improve lipid profile (78), liver function (79), ovarian function (80), beyond glycemic 
control. It is also evident that metformin reduces micro- and macro-vascular complications, and 
also alters gut microbiota (81), which may affect our results. Moreover, different probiotic strains 
were supplemented in included studies, and it is shown that strain variation may produce 
different effects on the host (82, 83). However, because of the small number of studies, it was not 
possible to assess strain-specific effects on interested outcomes. On the other hand, we assessed 
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liver function using liver enzymes, the factors that change in the later stages of liver damage. It is 
suggested that standard biomarkers such as ultrasound be used in future studies.  
Strengths and limitations 
As far as we are aware, this is the first meta-analysis comprehensively investigating the effect of 
probiotics/synbiotics supplementation on kidney and liver function in patients with type 2 
diabetes. However, one previous meta-analysis study investigated the effect of probiotic 
supplementation on kidney function in patients with diabetic nephropathy, with non-significant 
results (73). Pooling data from good quality RCTs permits causal associations to be drawn; 
however, there are some considerable limitations. First, the number of included studies was small 
for each outcome, which affects the validity of the results. Second, there was varied setting 
among studies, which made it difficult to assess the isolate effect of probiotic supplementation 
on the outcomes; including probiotic species, probiotic carrier, the medication used, and body 
weight. Third, although macronutrients intake was controlled in most of the included studies, 
fiber intake, or anti-oxidant nutrients (such as vitamin E, C, D, or omega-3) were not considered 
in analyses. Fourth, renal and liver biomarkers in most of the included studies were secondary 
outcomes, therefore, the studies may not have an adequate sample size to detect a significant 
association. Fifth, none of the included studies used gold standard biomarkers, resulting reduced 
validity of the results. Sixth, absence of any information on the composition of colon microbiota 
after the intervention with probiotics/synbiotics makes it difficult to draw conclusions about the 
effect of the supplement on changing the gut microbiota, which is suggested to be studied in 
future researches. Seventh, the certainty of evidence was low or very low; as, most of the 
included participants were from same location (Iran), and the point estimate was smaller than 5% 
baseline value of interested outcomes, leading to downgrading for inconsistency and 





In the present systematic review and meta-analysis, we assessed the effects of 
probiotics/synbiotic treatment on the liver and kidney biomarkers in patients with T2DM. The 
results of our meta-analysis indicated that probiotics/synbiotic treatment may reduce creatinine 
levels. However, due to the very low certainty of evidence, more clinical data using gold 
standard biomarkers are needed, globally, to clarify the role of probiotics, the most beneficial 
bacteria, and the optimal dosage in T2DM patients. 
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Table 1. PICOS criteria for inclusion and exclusion of studies 
Parameter  
Participants  Adults (≥18 years) of both sexes and all nationalities, with pre-diabetes 
or T2DM 




Placebo or non-fortified foods 
Outcomes Any biomarker of renal or liver function, including aspartate 
aminotransferase, alanine aminotransferase, gamma glutamyl 
transferase, alkaline phosphatase, bilirubin, creatinine, blood urea 
nitrogen, uric acid, microalbuminuria, proteinuria, or glomerular 
filtration rate, etc. 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Forest plot of randomized controlled clinical trials illustrating weighted mean 
difference (WMD) in A; ALP change (U/L), B: ALT change (U/L), C: AST change (U/L), and 
D: bilirubin change (mg/dl) between the probiotics/synbiotics supplementation and control 




Figure 3. Forest plot of randomized controlled clinical trials illustrating weighted mean 
difference (WMD) in A; creatinine change (mg/dl), B: GFR change (mL/min/1.73m2), C: 
microalbuminuria change (Alb/Cr (mg/gr)), and D: BUN change (mg/dl) between the 
probiotics/synbiotics supplementation and control groups for all eligible studies. Analysis was 
conducted using random effects model. 
 
 
 
 
 
 
 
